BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 19365281)

  • 1. Optimization of hypertension management: the role of angiotensin receptor blocker-calcium channel blocker combinations.
    Parati G
    J Cardiovasc Pharmacol; 2009 May; 53(5):352-8. PubMed ID: 19365281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiotensin receptor blocker and dihydropyridine calcium channel blocker combinations: an emerging strategy in hypertension therapy.
    Oparil S; Weber M
    Postgrad Med; 2009 Mar; 121(2):25-39. PubMed ID: 19332960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160).
    Ogawa H; Kim-Mitsuyama S; Jinnouchi T; Matsui K; Arakawa K
    Hypertens Res; 2009 Jul; 32(7):575-80. PubMed ID: 19444280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimizing management of hypertension with combination therapy: considerations for the nurse practitioner.
    Roberts ME; Epstein BJ
    J Cardiovasc Nurs; 2009; 24(5):380-9. PubMed ID: 19707098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Olmesartan/Amlodipine: combination therapy for the treatment of hypertension [corrected].
    Pimenta E
    Adv Ther; 2009 Jan; 26(1):1-11. PubMed ID: 19129998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose monotherapy vs low-dose combination therapy of calcium channel blockers and angiotensin receptor blockers in mild to moderate hypertension.
    Andreadis EA; Tsourous GI; Marakomichelakis GE; Katsanou PM; Fotia ME; Vassilopoulos CV; Diamantopoulos EJ
    J Hum Hypertens; 2005 Jun; 19(6):491-6. PubMed ID: 15759025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination therapy in hypertension: A focus on angiotensin receptor blockers and calcium channel blockers.
    Meka N; Katragadda S; Cherian B; Arora RR
    Am J Ther; 2010; 17(1):61-7. PubMed ID: 20090431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fixed-dose combinations of renin-angiotensin blocking agents with calcium channel blockers or hydrochlorothiazide in the treatment of hypertension.
    Bramlage P
    Expert Opin Pharmacother; 2009 Aug; 10(11):1755-67. PubMed ID: 19538001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of cardiovascular risk with RAS inhibitor/CCB combination therapy.
    Dahlöf B
    J Hum Hypertens; 2009 Feb; 23(2):77-85. PubMed ID: 18685606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Hypertension 2007-2008].
    Chatzikyrkou C; Menne J; Haller H
    Med Klin (Munich); 2009 Aug; 104(8):614-21. PubMed ID: 19701732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fixed-combination therapies in hypertension management: focus on enalapril/lercanidipine.
    Tocci G; Palano F; Pagannone E; Chin D; Ferrucci A; Volpe M
    Expert Rev Cardiovasc Ther; 2009 Feb; 7(2):115-23. PubMed ID: 19210207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical experience in treating hypertension with fixed-dose combination therapy: angiotensin II receptor blocker losartan plus hydrochlorothiazide.
    Abe M; Okada K; Matsumoto K
    Expert Opin Drug Metab Toxicol; 2009 Oct; 5(10):1285-303. PubMed ID: 19761411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improving blood pressure control and clinical outcomes through initial use of combination therapy in stage 2 hypertension.
    White WB
    Blood Press Monit; 2008 Apr; 13(2):123-9. PubMed ID: 18347448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complementary mechanisms of angiotensin receptor blockers and calcium channel blockers in managing hypertension.
    Neutel JM
    Postgrad Med; 2009 Mar; 121(2):40-8. PubMed ID: 19332961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of Angiotensin receptor blocker and calcium channel blocker combination therapy in treating hypertension: focus on recent studies.
    Chrysant SG
    Am J Cardiovasc Drugs; 2010; 10(5):315-20. PubMed ID: 20860414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prescribing patterns in hypertension: the emerging role of fixed-dose combinations for attaining BP goals in hypertensive patients.
    Neutel JM
    Curr Med Res Opin; 2008 Aug; 24(8):2389-401. PubMed ID: 18616863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blood pressure and metabolic effect of a combination of lercanidipine with different antihypertensive drugs in clinical practice.
    Cicero AF; Gerocarni B; Rosticci M; Borghi C
    Clin Exp Hypertens; 2012; 34(2):113-7. PubMed ID: 21967031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mitigation of calcium channel blocker-related oedema in hypertension by antagonists of the renin-angiotensin system.
    de la Sierra A
    J Hum Hypertens; 2009 Aug; 23(8):503-11. PubMed ID: 19148104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-pill combination of amlodipine and valsartan in the management of hypertension.
    Flack JM; Hilkert R
    Expert Opin Pharmacother; 2009 Aug; 10(12):1979-94. PubMed ID: 19606937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The combination of an ACE inhibitor and a calcium channel blocker is an optimal combination for the treatment of hypertension].
    Widimský J
    Vnitr Lek; 2009 Feb; 55(2):123-30. PubMed ID: 19348394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.